Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
JOURNAL OF CLINICAL ONCOLOGY. Bd. 40. H. 4. 2022
Erscheinungsjahr: 2022
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Shitara, Kohei (Autor)
Janjigian, Yelena Y. (Autor)
Moehler, Markus H. (Autor)
Garrido, Marcelo (Autor)
Gallardo, Carlos (Autor)
Shen, Lin (Autor)
Yamaguchi, Kensei (Autor)
Wyrwicz, Lucjan (Autor)
Skoczylas, Tomasz (Autor)
Silva, Arinilda (Autor)
Bragagnoli, Campos (Autor)
Liu, Tianshu (Autor)
Tehfe, Mustapha (Autor)
Elimova, Elena (Autor)
Soleymani, Samira (Autor)
Lei, Ming (Autor)
Kondo, Kaoru (Autor)
Li, Mingshun (Autor)
Ajani, Jaffer A. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
